Abstract
This paper focuses on developing a lipid-based vaccine targeting nasopharyngeal carcinoma (NPC), a highly severe and invasive epithelial malignancy associated with the Epstein-Barr virus (EBV). The researchers selected EBV latent membrane protein 2 (LMP2) as the preferred antigen for the vaccine. They synthesized full-length LMP2 using an in vitro transcription method and encapsulated it into cationic liposomes based on (2,3-dioleacyl propyl) trimethylammonium chloride (DOTAP) to create the mRNA vaccine (LPX-mLMP2). Cell assays in the study demonstrated that antigen-presenting cells efficiently took up LPX-mLMP2 and expressed LMP2. This led to the formation of peptide-major histocompatibility complexes (pMHC) for presentation. Moreover, the proliferation of antigen-specific T cells at the tumor site indicated the promising potential for mRNA vaccines in combating virus-induced cancers, such as NPC. The researchers concluded that the newly developed mRNA vaccine encoding the antigen offered advantages in the context of NPC and highlighted the attractiveness of mRNA vaccines as candidates for cancer immunotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
